Stephan Eder from STADA became a new president of Medicines for Europe
Stephan Eder, Head of Western Europe & Germany at Stada, has been elected by the Board of Medicines for Europe as its President for a two-year term (2025-2027).
Eder outlined the following policy priorities which will shape his mandate:
1. Facilitate sustainable market policies that recognise the full value of the off-patent medicines sector in delivering access.
2. Support a vibrant off-patent medicines manufacturing sector in Europe.
3. Build a strong environmental, social and governance agenda for medicines with patient access at its core.
Eder stated: “The off-patent medicines industry plays a critical role in public health and must be central to industrial, economic and environmental policy decisions. Seven out of every 10 medicines dispensed in Europe are generic medicines, including nine out of 10 on the EU Critical Medicines List, while the industry directly employs almost 200,000 highly qualified people. Ensuring the sustainability of this essential sector is vital for healthcare systems throughout Europe.”
Eder thanked outgoing President Elisabeth Stampa (Medichem) for her many achievements in advancing equitable access to medicines during her mandate, including safeguarding medicine supplies during high-cost inflation, supporting patients in Ukraine through coordinated donations, advocating for balanced intellectualproperty provisions in the EU pharmaceutical legislation review, and placing the Critical Medicines Act high on the European Union’s political agenda. "I look forward to drawing on the experience and expertise of both Elisabeth and Polpharma’s Markus Sieger in their roles as Medicines for Europe vice-presidents,” Eder commented. At the same time, Marc Crouton, President Region Europe at Fresenius Kabi, and Sandoz President Europe, Christophe Delenta, were elected to Medicines for Europe’s Executive Committee until 2027.
About Stephan Eder
Stephan Eder has more than 20 years of experience in the healthcare industry. As a member of STADA's global management team since 2020, he oversees Western European markets, including Germany. Prior to STADA, he held various international management positions at Novartis, Sandoz and Hexal.
